ELV SEC Filings

Elevance Health, Inc. (ELV) reported a year of increased revenue and strategic acquisitions, but saw a slight decrease in net income for the year ended December 31, 2025. Total operating revenue grew by 12.8% to $197.6 billion, driven by premium rate increases across its Health Benefits segment, growth in Medicare Advantage, and the impact of acquisitions. However, shareholders' net income declined by 5.3% to $5.66 billion, or $25.21 per diluted share, primarily due to higher medical cost trends within the Health Benefits segment and increased investments in technology and workforce. The company experienced a 1.1% decrease in total medical membership, largely due to Medicaid redeterminations and attrition in other segments, partially offset by growth in Medicare Advantage and Individual businesses. Key strategic moves during the year included the acquisition of Centers and CareBridge, aimed at strengthening its Medicaid and long-term care offerings and its Carelon Services segment. The company also managed its capital effectively, repurchasing shares and paying dividends, while maintaining a strong liquidity position. Looking ahead, Elevance Health is navigating evolving regulatory landscapes and persistent medical cost pressures.

Elevance Health, Inc. (ELV) filed a Current Report (8-K) on January 28, 2026, to report its fourth quarter and full year 2025 financial results. The press release containing these results is furnished as an exhibit to this filing. Investors should note that the information provided in this 8-K, specifically within Item 2.02 and Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information will not be incorporated by reference into any future SEC filings unless explicitly stated. The report also includes a standard forward-looking statements disclaimer, outlining the inherent risks and uncertainties that could cause actual results to differ materially from any projections. Investors are advised to review the detailed risk factors discussed in Elevance Health's other SEC filings, as these forward-looking statements speak only as of the filing date and are not updated for subsequent events.

Elevance Health, Inc. (ELV) has announced a significant addition to its Board of Directors through an 8-K filing on December 10, 2025. The company elected Amy W. Schulman as an independent director, effective January 12, 2026, with her term extending to the 2028 annual meeting of shareholders. This appointment is notable as Ms. Schulman brings expertise that has also led to her appointment on the Audit and Finance Committees, positions critical for financial oversight. Investors should note that Ms. Schulman has been deemed an independent director by both NYSE listing standards and the company's own guidelines. Furthermore, she meets the criteria for an "audit committee financial expert" according to SEC regulations, underscoring her qualifications for these key financial governance roles. Her compensation will follow the company's standard non-employee director program. The company also furnished a press release detailing this election as an exhibit.

Elevance Health, Inc. (ELV) has filed an 8-K report on November 10, 2025, primarily to reaffirm its financial guidance for the full year 2025 during upcoming investor meetings. The company expects to maintain its previously issued earnings per diluted share guidance of approximately $24.70. This figure notably includes approximately $5.30 per diluted share attributable to net unfavorable items. Excluding these specific items, Elevance Health anticipates adjusted earnings per diluted share to remain at approximately $30.00, consistent with prior expectations and not incorporating any additional adjustments beyond those already reported in the third quarter of 2025. In addition to earnings guidance, the company also reaffirmed its full-year 2025 benefit expense ratio guidance, projecting it to be around 90.0%. Management attributes these expectations to their current assessment of market conditions, operational performance, the prevailing regulatory and policy environment, and refined business assumptions, including cost trends and medical claims payable estimates. Investors are reminded that actual results could materially differ from these projections due to potential changes in business factors or underlying assumptions.

Elevance Health, Inc. (ELV) reported its financial results for the third quarter and the first nine months of fiscal year 2025. The company demonstrated revenue growth driven by premium rate increases and expansion in its Medicare Advantage business, partially offset by Medicaid attrition. Net income saw an increase for the quarter, but a decrease for the nine-month period, influenced by factors such as investment performance, interest expenses, and tax impacts. Total assets grew to $122.8 billion from $116.9 billion at year-end 2024, with increases in current assets like premiums receivables and other receivables. Liabilities also increased, primarily due to higher medical claims payable and long-term debt. The company continues to manage its capital through dividends and share repurchases, while also investing in strategic acquisitions and business optimization initiatives. Regulatory changes and market dynamics, particularly in the healthcare landscape, remain key considerations for future performance.

Elevance Health, Inc. (ELV) has filed a Current Report (8-K) on October 21, 2025, to report its financial results for the quarter ended September 30, 2025. This filing primarily serves to attach a press release containing the detailed financial outcomes. While specific financial figures are not embedded within the 8-K itself, the report signifies the official release of these results to the public and the market. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive details on revenue, earnings, and other key performance indicators for the third quarter of 2025. The report also includes a standard 'Forward-Looking Statements' section, cautioning investors about the inherent risks and uncertainties associated with future projections. These statements, based on current expectations, are subject to various factors that could cause actual results to differ materially. The company highlights potential risks including changes in healthcare costs, regulatory environments, cyber security threats, competitive pressures, and the performance of government programs like Medicare and Medicaid. Investors are advised to review these disclosures carefully alongside the financial results.

Elevance Health, Inc. (ELV) has successfully closed a significant notes offering totaling approximately $3.0 billion. This issuance includes four tranches with varying interest rates and maturity dates: $750 million in 4.000% Notes due 2028, $750 million in 4.600% Notes due 2032, $1,000 million in 5.000% Notes due 2036, and $500 million in 5.700% Notes due 2055. The company raised approximately $2,972.7 million in net proceeds after deducting underwriting discounts and expenses. The primary use of these proceeds is to refinance existing debt, specifically repaying or redeeming $400 million of 5.350% senior notes due 2025 and repurchasing $500 million of 4.900% senior notes due 2026. The remaining funds are earmarked for general corporate purposes, including potential acquisitions, further debt reduction, and share repurchases. This strategic refinancing aims to optimize the company's debt structure and financial flexibility.

Elevance Health, Inc. (ELV) has issued a Current Report (8-K) on September 4, 2025, primarily to reaffirm its financial guidance for the full year 2025. The company expects to report diluted earnings per share of approximately $24.10, which includes an estimated $5.90 per diluted share in net unfavorable items. Excluding these specific items, the adjusted earnings per share are projected to be around $30.00, consistent with prior disclosures and not accounting for any additional adjustments beyond those already reported in the second quarter of 2025. Furthermore, Elevance Health is reiterating its guidance for the full year 2025 benefit expense ratio, which is anticipated to be approximately 90.0%. Management attributes these expectations to their current assessment of market conditions, operational performance, the regulatory and policy environment, and refined assumptions regarding cost trends and medical claims payable estimates. Investors are cautioned that actual results may differ materially due to changes in these factors.

Elevance Health, Inc. (ELV) announced a change to its Board of Directors through an 8-K filing dated July 28, 2025. The company elected Steven H. Collis as an independent director, effective August 1, 2025, with his term set to conclude at the 2027 annual shareholder meeting. This appointment is a key governance update that investors should note, particularly given Mr. Collis's qualifications and committee assignments. Mr. Collis brings valuable expertise to the Board, as evidenced by his appointment to both the Audit and Finance Committees. Notably, he has been designated as an "audit committee financial expert" by the SEC, suggesting a strong financial acumen that can contribute to oversight of the company's financial reporting and internal controls. His compensation will align with the company's existing non-employee director compensation structure.

Elevance Health, Inc. reported a decrease in net income for the three and six months ended June 30, 2025, compared to the prior year, primarily driven by increased benefit expenses and higher net losses on financial instruments. Despite the net income decline, total operating revenue saw a significant increase of 14.3% and 14.8% for the respective periods, driven by premium rate increases in the Health Benefits segment, recent acquisitions, and membership growth in Medicare Advantage and Individual ACA businesses. The company is actively managing its capital, evidenced by continued share repurchases and dividend payments, while also navigating evolving regulatory landscapes and integrating recent acquisitions. Key financial shifts include a substantial increase in benefit expenses due to higher medical cost trends, particularly in the Medicaid and Affordable Care Act (ACA) plans, which more than offset revenue growth in the Health Benefits segment. Conversely, the CarelonRx and Carelon Services segments demonstrated strong revenue and operating gain growth. The company maintained a solid liquidity position, with net cash provided by operating activities increasing year-over-year, supported by favorable working capital impacts.

Elevance Health, Inc. (ELV) has filed a Current Report (8-K) on July 17, 2025, to report its financial results for the fiscal quarter ended June 30, 2025. The primary purpose of this filing is to furnish a press release detailing these results, which is included as an exhibit. Investors should note that the information provided in this Item 2.02 and the attached press release is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor will it be automatically incorporated into future SEC filings unless specifically referenced. While the specific financial figures are not detailed within the 8-K text itself but are contained within the referenced press release (Exhibit 99.1), this filing serves as official notification of the company's quarterly performance disclosure. Investors are advised to consult the press release for detailed financial metrics, including revenue, earnings, and any guidance provided. The filing also includes standard forward-looking statement disclaimers, highlighting the inherent risks and uncertainties associated with such projections, which could cause actual results to differ materially from expectations.

Elevance Health, Inc. has filed an 8-K report to reaffirm its financial guidance for the full year 2025. The company expects diluted earnings per share to be in the range of $28.30 to $29.00, which includes approximately $5.85 per diluted share in net unfavorable items. Excluding these specific items, the adjusted earnings per diluted share are projected to be between $34.15 and $34.85, consistent with prior statements and not incorporating additional adjustments beyond those reported in Q1 2025. Furthermore, Elevance Health is reiterating its full-year 2025 guidance for the benefit expense ratio, targeting 89.1% with a 50 basis point margin of error. The company also anticipates that 60% of its adjusted shareholders' earnings per diluted share will be realized in the first half of 2025. These reaffirmations reflect management's current assessment of market conditions, operational performance, regulatory environments, and refined business assumptions. Investors are reminded that actual results may differ materially due to inherent uncertainties and risks outlined in the company's SEC filings.

Elevance Health, Inc. (ELV) filed an 8-K on May 14, 2025, detailing the outcomes of its Annual Meeting of Shareholders held on May 13, 2025. The report indicates strong shareholder support for the election of directors, with all nominated individuals securing substantial majorities for three-year terms. Additionally, shareholders provided an advisory vote of approval for the company's executive compensation, signaling confidence in the current compensation structure. The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was also overwhelmingly ratified. However, a shareholder proposal requesting a report on the effectiveness of Diversity, Equity, and Inclusion (DEI) efforts did not receive majority approval from shareholders. This suggests a divergence of opinion on the urgency or format of reporting on DEI initiatives among the company's investor base. The results of these votes are important for understanding shareholder sentiment regarding corporate governance, executive pay, and key ESG-related initiatives at Elevance Health.

Elevance Health, Inc. (ELV) has filed an 8-K report on April 22, 2025, to announce its financial results for the first quarter ended March 31, 2025. This filing primarily serves as a notification of the press release containing these results, which is attached as Exhibit 99.1. Investors should refer to the press release for specific financial figures and performance metrics. The report also includes standard forward-looking statements, outlining potential risks and uncertainties that could impact the company's future financial performance. These include risks related to healthcare costs, regulatory changes, cybersecurity, competitive pressures, and government programs like Medicare and Medicaid.

Elevance Health, Inc. (ELV) reported its first-quarter 2025 financial results, demonstrating robust top-line growth driven by premium rate increases and membership gains in key segments like Medicare Advantage and Individual ACA. Total operating revenue increased by 15.4% year-over-year to $48.8 billion, while net income saw a slight decrease of 2.9% to $2.18 billion. This dip in net income was influenced by increased benefit expenses reflecting higher medical cost trends, and a rise in net losses on financial instruments. Despite these pressures, the company maintained its competitive position with a solid operating gain and a slight increase in diluted earnings per share to $9.61. The company continues to execute its strategic growth initiatives, including key acquisitions in the long-term care and home and community-based services sectors, reinforcing its diversified healthcare offerings.

Elevance Health, Inc. (ELV) has filed a Current Report (8-K) on April 17, 2025, providing a pre-release of its first quarter 2025 financial results. The company anticipates reporting GAAP earnings per diluted share of $9.61, which includes approximately $2.36 per diluted share from unfavorable items. Excluding these, adjusted earnings per diluted share are expected to be $11.97. This performance reflects medical cost trends aligning with expectations, even within the Medicare Advantage segment where costs remain elevated but are consistent with the company's pricing and outlook. Crucially for investors, Elevance Health intends to reaffirm its full-year 2025 adjusted net income guidance, projecting it to be between $34.15 and $34.85 per diluted share. The company also anticipates its Medicare Advantage membership to remain within the previously provided range of 2,200 to 2,250 thousand members for the full year. More comprehensive details regarding first quarter results and the updated full-year outlook will be disclosed during the official earnings release on April 22, 2025.

Elevance Health, Inc. has reaffirmed its 2025 earnings per diluted share guidance, projecting it to be between $30.40 and $31.10. This guidance includes approximately $3.75 per diluted share attributed to net unfavorable items. Excluding these specific items, the company anticipates adjusted earnings per diluted share to range from $34.15 to $34.85. Furthermore, Elevance Health expects its total medical enrollment for the full year 2025 to align with projections previously shared in its Fourth Quarter 2024 Earnings Release. Notably, this includes an expectation for Medicare Advantage membership to fall between 2.2 million and 2.25 million members. These reaffirmations are being communicated as company officers engage with investors over the coming weeks.

Elevance Health, Inc. (ELV) reported a stable financial performance for the year ended December 31, 2024, with total operating revenue increasing by 2.9% to $175.2 billion. This growth was primarily driven by premium rate increases across its health plans, expansion in its CarelonRx segment, and contributions from recent acquisitions. Net income remained relatively flat year-over-year at $5.97 billion, reflecting a slight decrease of 0.3%. Diluted Earnings Per Share (EPS) saw a modest increase of 1.8% to $25.68, attributed to a reduction in diluted shares outstanding due to share repurchases. The company experienced a notable decline in Medicaid membership (down 15.1%), largely due to eligibility redeterminations and market exits, which impacted benefit expenses. However, this was partially offset by growth in Employer Group fee-based, Individual, and FEP businesses. Strategic initiatives are ongoing, including the integration of acquired businesses like Paragon Healthcare and CareBridge, and the divestiture of life and disability businesses. Management is focused on optimizing operations and managing healthcare costs through value-based care models and medical management programs. The company maintains a strong liquidity position and ended the year with $35.7 billion in cash, cash equivalents, and investments. Key risks identified include managing healthcare costs, regulatory changes, and cybersecurity threats.

Elevance Health, Inc. (ELV) has filed an 8-K report on January 23, 2025, to announce its fourth quarter and full-year 2024 financial results. The core of this filing is the press release, furnished as an exhibit, which details the company's performance for the period ended December 31, 2024. Investors should review this press release for specific financial metrics, including revenue, earnings per share, and any key operational updates or forward-looking guidance provided by the company. The filing also includes standard forward-looking statement disclaimers and a list of exhibits, with the press release being the primary document of interest for immediate financial insights.

Elevance Health, Inc. (ELV) has announced the successful closing of a significant notes offering, raising approximately $5.138 billion in net proceeds. This offering comprises multiple series of notes with varying interest rates and maturity dates, ranging from 2026 to 2064. The company intends to utilize these proceeds for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This strategic move provides Elevance Health with substantial liquidity to fuel its growth initiatives and manage its capital structure. Investors should note the diversified debt maturity profile and the stated uses of proceeds, which suggest a focus on both strategic growth and shareholder returns. The terms of the notes include provisions for redemption and a change of control clause that offers protection to noteholders under specific circumstances.

Elevance Health, Inc. (ELV) filed an 8-K on October 17, 2024, primarily to report its financial results for the third quarter ended September 30, 2024. The filing includes a press release (Exhibit 99.1) detailing these results. While the specific financial figures are not presented within the 8-K text itself, this report serves as the official notification to the market of their latest quarterly performance. Investors should refer to the furnished press release for detailed financial metrics, including revenue, earnings, and any forward-looking guidance provided by the company. This report also includes standard forward-looking statements that caution investors about potential risks and uncertainties that could cause actual results to differ from projections. These risks are typical for a health insurer and cover areas such as healthcare costs, regulatory changes, operational and technological challenges, competitive pressures, and government program risks (Medicare/Medicaid). Investors are advised to review these risks carefully, as they provide context for the company's financial performance and future outlook.

Elevance Health, Inc. reported a net income of $1,008 million for the third quarter of 2024, a decrease from $1,300 million in the same period last year. Diluted earnings per share (EPS) were $4.36, down from $5.45 year-over-year. For the nine-month period, net income increased to $5,558 million from $5,160 million in 2023, with EPS rising to $23.81 from $21.56. Total operating revenue for the third quarter increased by 5.3% to $44,719 million, driven by premium rate increases and growth in CarelonRx. However, this was partially offset by a decline in Medicaid membership due to eligibility redeterminations. The company also incurred a $666 million accrual for the anticipated Provider Settlement Agreement related to the BCBSA litigation, impacting operating gain. Total assets grew to $116,533 million from $108,928 million at the end of 2023, supported by increased investments and property and equipment. The company continues to return capital to shareholders through dividends and share repurchases, with $11,111 million available for future repurchases. Elevance Health announced two pending acquisitions expected to close in late 2024 or early 2025, aimed at expanding its long-term care and home and community-based services.

Elevance Health, Inc. filed an 8-K report on July 17, 2024, to furnish a press release detailing its financial results for the second quarter ended June 30, 2024. The filing primarily serves to inform investors about the company's performance during the quarter, although the specific financial figures are not included in the 8-K text itself but are referenced as being in the furnished press release (Exhibit 99.1). Investors should note that this report, along with the press release, contains forward-looking statements that are subject to various risks and uncertainties. Elevance Health cautions that actual results could differ materially from those projected due to a range of factors, including healthcare cost trends, regulatory changes, operational risks, cyber security threats, competitive pressures, and macroeconomic conditions. The company emphasizes that these forward-looking statements speak only as of the filing date, and they do not undertake to update them.

Elevance Health, Inc. (ELV) reported its financial results for the second quarter and first half of 2024. For the quarter ended June 30, 2024, total revenues grew slightly to $43.9 billion from $43.7 billion in the prior year quarter. Shareholders' net income saw a significant increase of 24.1% to $2.3 billion, translating to diluted EPS of $9.85, up from $7.79 a year ago. This improvement was driven by better operating performance across all segments, a gain on the sale of its life and disability business, and increased net investment income, partially offset by higher income tax expense. The first six months of 2024 also showed positive trends, with total revenues increasing to $86.5 billion and shareholders' net income rising by 18.3% to $4.5 billion, resulting in diluted EPS of $19.44, up from $16.10 in the same period last year. The company highlighted strong growth in its CarelonRx and Carelon Services segments. However, total medical membership saw a decline of 4.6%, primarily due to Medicaid membership attrition following eligibility redeterminations, which the company expects to offset with growth in its commercial plans. Elevance Health completed the acquisition of Paragon Healthcare, Inc. in March 2024, further bolstering its CarelonRx segment. The company also announced an agreement to acquire Centers Plan for Healthy Living LLC, expected to close in the third quarter of 2024. The sale of its life and disability businesses in April 2024 contributed a $240 million gain. The company repurchased $1.03 billion of its common stock in the first half of 2024, demonstrating a commitment to returning capital to shareholders.

Elevance Health, Inc. filed an 8-K on June 12, 2024, primarily to reaffirm its financial guidance for the full year 2024. The company indicated that officers will be speaking with investors and intend to reaffirm the previously issued net income guidance. Specifically, Elevance expects full-year 2024 net income to be greater than $34.05 per diluted share. This includes an estimated $3.15 per diluted share attributed to net unfavorable items. Excluding these specific unfavorable items, Elevance Health continues to anticipate adjusted net income to be greater than $37.20 per diluted share. Investors should note that this guidance is based on information available as of the first quarter of 2024 earnings release and does not incorporate any further adjustments not previously disclosed. The filing also includes standard forward-looking statements and risk factors that investors should consider.

Elevance Health, Inc. (ELV) announced on May 29, 2024, the closing of a significant notes offering, raising approximately $2.57 billion in net proceeds. This offering included $600 million in 5.150% Notes due 2029, $1 billion in 5.375% Notes due 2034, and $1 billion in 5.650% Notes due 2054. The company intends to use these funds for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This financing action provides Elevance Health with substantial liquidity to support its strategic initiatives and financial flexibility. Investors should note the specific interest rates and maturity dates associated with each tranche of notes, as well as the terms for redemption and potential change of control provisions that could trigger an accelerated repurchase of the notes. The company's ability to continue incurring debt under the indenture provides further operational flexibility.

Elevance Health, Inc. (ELV) filed an 8-K on May 15, 2024, reporting the results of its Annual Meeting of Shareholders held on May 14, 2024. The filing indicates that all director nominees were elected for three-year terms, demonstrating continued shareholder confidence in the company's leadership. Additionally, shareholders provided an advisory vote approving the compensation of the company's named executive officers. This suggests alignment between shareholder interests and executive compensation strategies. The company also successfully ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for 2024, a standard but important procedural vote for financial oversight. A notable outcome was the rejection of a shareholder proposal requesting annual political activity reporting from certain third parties prior to company donations. This indicates that a majority of shareholders did not support this specific disclosure initiative at this time.

Elevance Health, Inc. reported solid financial results for the first quarter of 2024, demonstrating resilience and strategic execution in a dynamic healthcare landscape. Total revenues saw a modest increase of 1.0% to $42.6 billion, driven by premium rate adjustments and growth in its CarelonRx segment. Net income rose by a significant 12.2% to $2.25 billion, leading to a diluted Earnings Per Share (EPS) of $9.59, a 15.5% increase year-over-year. This performance was supported by improved operating gains across its Health Benefits, Carelon Services, and CarelonRx segments, coupled with a decrease in amortization of intangible assets and higher net investment income. Operationally, the company experienced a 3.9% decline in total medical membership, largely due to Medicaid redetermination effects and some attrition in employer group and Medicare segments. However, this was partially offset by growth in Individual, Employer Group fee-based, BlueCard, and FEHB memberships. Strategic acquisitions, such as Paragon Healthcare, Inc., and pending acquisitions like Centers Plan for Healthy Living LLC, underscore Elevance Health's commitment to expanding its care delivery capabilities and market reach. The company also announced the divestiture of its life and disability businesses, signaling a sharpened focus on its core health insurance and healthcare services operations.

Elevance Health, Inc. filed an 8-K on April 18, 2024, primarily to furnish a press release detailing its financial results for the first quarter ended March 31, 2024. This filing provides investors with the company's latest performance metrics and operational updates. The press release, incorporated by reference, contains key financial figures and management commentary. While the 8-K itself doesn't introduce new operational details beyond what's in the press release, it signifies the official reporting of these results to the SEC. Investors should refer to the furnished press release (Exhibit 99.1) for a comprehensive understanding of Elevance Health's Q1 2024 performance, including revenue, earnings, and any forward-looking statements or outlook provided by the company. The filing also includes standard disclaimers regarding forward-looking statements and their inherent risks.

Elevance Health, Inc. (ELV) filed an 8-K on March 4, 2024, primarily to reaffirm its full-year 2024 financial guidance and to announce positive developments regarding its Medicare Advantage Star Ratings. The company reiterated its net income guidance to be greater than $34.29 per diluted share, and adjusted net income to be greater than $37.10 per diluted share, after accounting for approximately $2.81 per diluted share in unfavorable items. Furthermore, Elevance Health received notification from the Centers for Medicare & Medicaid Services (CMS) that four of its Medicare Advantage contracts received an updated, higher Star Rating. This positive revision means that the company now expects approximately 49% of its Medicare Advantage members to be enrolled in plans rated at least 4-Star for the 2024 Star Ratings (which impacts payment year 2025 revenue). The company estimates this reconsideration will add approximately $190 million to its payment year 2025 revenue, a notable benefit for future financial performance.

Elevance Health, Inc. (ELV) reported strong revenue growth for the fiscal year ended December 31, 2023, with total operating revenue increasing by 9.3% to $170.2 billion. This growth was primarily driven by premium rate increases in its Health Benefits segment and expansion in its CarelonRx pharmacy business, including the acquisition of BioPlus. Net income saw a modest increase of 1.7% to $5.99 billion, resulting in diluted earnings per share of $25.22, up 3.9%. The company experienced a decline in Medicaid membership due to the resumption of eligibility redeterminations, but this was offset by growth in Individual Public Exchange and Medicare Advantage membership. Elevance Health continues to manage healthcare costs effectively through various programs and pricing strategies, while also investing in digital transformation and expanding its Carelon brand for healthcare services. The company's financial health remains solid, with a debt-to-capital ratio of 38.9% as of December 31, 2023. Elevance Health also announced strategic acquisitions and a pending divestiture, signaling ongoing efforts to refine its business portfolio and enhance its market position.

Elevance Health, Inc. (ELV) announced a quarterly cash dividend of $1.63 per share on January 23, 2024. This action by the Audit Committee of the Board of Directors demonstrates a continued commitment to returning capital to shareholders. The dividend payment is scheduled for March 22, 2024, with a record date of March 8, 2024, providing a clear timeline for investors to participate in this distribution.

Elevance Health, Inc. filed an 8-K on January 24, 2024, to report its financial results for the quarter ended December 31, 2023. The filing primarily consists of a press release detailing these results, which is furnished as an exhibit. Investors should note that this information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it carries a different legal weight than a formally filed financial statement. The press release contains forward-looking statements that provide management's expectations for future financial performance and operational plans. Investors are cautioned to consider these statements in light of the numerous risks and uncertainties outlined in the filing, which could lead to material differences between projected and actual results. These risks encompass various factors, including healthcare cost trends, regulatory changes, operational disruptions, competitive pressures, and potential litigation.

Elevance Health, Inc. (ELV) filed an 8-K on October 17, 2023, to report its financial results for the quarter ended September 30, 2023. The primary purpose of this filing is to provide investors with the company's latest financial performance through a furnished press release (Exhibit 99.1). While the 8-K itself doesn't contain the detailed results, it formally announces the availability of this information, allowing investors to access the press release for a comprehensive overview of revenue, earnings, and other key financial metrics for the specified period. This report serves as a notification to the market that Elevance Health has released its quarterly financial update. Investors and analysts should refer to the press release, Exhibit 99.1, for specific figures and management commentary on operational performance, growth drivers, and the company's outlook. The filing also includes standard forward-looking statement disclaimers, advising caution regarding future projections due to inherent business risks and uncertainties in the healthcare industry.

Elevance Health, Inc. (ELV) reported its financial results for the third quarter and the first nine months of 2023. For the three months ending September 30, 2023, total revenues increased by 7.3% year-over-year to $42.85 billion, driven by higher premium revenues and growth in CarelonRx pharmacy revenue. However, net income saw a decline of 18.6% to $1.30 billion, primarily due to business optimization charges and increased net losses on financial instruments. The nine-month period showed a more positive trend in net income, which increased by 3.0% to $5.16 billion. Total operating revenue grew by 10.1% to $127.76 billion for the nine months. The company experienced a slight increase in total medical membership, with growth in Individual Public Exchange and Medicare Advantage products offsetting declines in Medicaid. Management is focused on efficiency programs and strategic acquisitions/divestitures, including the pending acquisition of Blue Cross Blue Shield of Louisiana. Key financial highlights include strong revenue growth, a slight increase in medical membership, and robust operating cash flow generation. However, the quarter was impacted by significant business optimization charges, leading to a year-over-year decrease in quarterly net income and EPS.

Elevance Health, Inc. (ELV) has disclosed via an 8-K filing on October 13, 2023, that its 2024 Medicare Advantage Star Ratings are projected to significantly decline. Specifically, the percentage of members in plans rated 4 Stars or higher is expected to drop from approximately 64% (based on 2023 ratings) to about 34%. This decline is primarily attributed to three large contracts, representing 36% of Medicare Advantage members, that are moving from 4 or 4.5 Stars to 3.5 Stars. The company attributes this performance dip to challenges in Consumer Assessment of Healthcare Providers and Systems (CAHPS) measures, such as perceived access to care, and the impact of CMS's new outlier methodology, which raised cut points for ratings. While the company expresses disappointment and outlines ongoing investments in service, product, network, and operations to improve future performance, it also notes that the financial impact on Star quality bonus payments and plan-level rebates will not be felt until 2025. Elevance Health is actively exploring mitigation strategies, including contract diversification and operational initiatives, to offset potential earnings headwinds. Despite this anticipated rating decline, the company highlights positive performance in specific areas, such as all plans in Florida achieving at least 4.5 Stars, with two receiving a perfect 5 Stars, and strong ratings in Puerto Rico and other select states. Investors should monitor the company's efforts to improve Star ratings and its success in mitigating the financial consequences of this development.

Elevance Health, Inc. (ELV) announced on October 4, 2023, an amendment to its Bylaws, effective immediately. This update is primarily driven by the need to align with the Securities and Exchange Commission's (SEC) "universal proxy" rules (Rule 14a-19). The amendments introduce new procedural and informational requirements for shareholders intending to nominate directors at company meetings. Key changes include enhanced disclosure requirements for nominating shareholders regarding their plans and agreements related to the company's securities, a certification mandate to confirm compliance with universal proxy rules regarding proxy statement distribution, and the reservation of a specific proxy card color for the Board's use. These modifications aim to standardize and clarify the director nomination and proxy solicitation processes, ensuring compliance with regulatory updates and potentially strengthening the Board's governance procedures in the context of shareholder activism.

Elevance Health, Inc. (ELV) reported solid financial results for the quarter ending June 29, 2023, demonstrating continued growth and operational strength. Total revenues increased by 12.7% year-over-year for the quarter, driven by strong performance in its Health Benefits segment and growth in CarelonRx. Net income saw a healthy increase of 13.6% compared to the prior year's quarter, reflecting improved operating gains and efficient cost management. The company also reported a significant increase in operating cash flow, highlighting its ability to generate substantial cash from its core operations. Membership continued to grow, particularly in Medicaid and Medicare Advantage, underscoring the company's expanding reach in key government programs. Key strategic initiatives are progressing, including the pending acquisition of Blue Cross and Blue Shield of Louisiana, which is expected to further enhance the company's market position. Management highlighted prudent capital allocation, including ongoing share repurchases and dividend payments, reinforcing its commitment to shareholder value. Despite the dynamic healthcare landscape, Elevance Health has demonstrated resilience and strategic execution, positioning it favorably for future growth.

Elevance Health, Inc. (ELV) issued a Current Report (8-K) on September 20, 2023, primarily to reaffirm its financial guidance for the full year 2023. The company expects net income to be greater than $29.09 per share. This figure includes approximately $3.76 per share of net unfavorable items. Excluding these specific unfavorable items, Elevance Health maintains its expectation for adjusted net income to exceed $32.85 per share. This guidance remains consistent with information previously provided in the company's second quarter 2023 earnings release and does not account for any additional adjustment items beyond those already reported.

Elevance Health, Inc. (ELV) announced a significant leadership change in its finance department via an 8-K filing on August 8, 2023. Mark Kaye has been appointed as the new Executive Vice President and Chief Financial Officer (CFO), effective November 1, 2023. Mr. Kaye will join the company as CFO Designate on September 6, 2023, preparing for his transition into the CFO role. This appointment follows the retirement of John Gallina, who has served the company for nearly three decades and will transition to a Special Advisor to the CEO role. Mr. Kaye brings extensive financial leadership experience from his previous roles at Moody's Corporation and Massachusetts Mutual Life Insurance Company, among others. In addition to the leadership transition, Elevance Health reaffirmed its full-year 2023 net income guidance. The company expects net income to be greater than $29.09 per share, with approximately $3.76 per share attributed to unfavorable items. Excluding these items, the adjusted net income guidance remains strong, expected to be greater than $32.85 per share. This reaffirmation of guidance suggests continued confidence in the company's financial performance for the remainder of the fiscal year.

Elevance Health, Inc. (ELV) filed an 8-K on July 19, 2023, to report its financial results for the second quarter ended June 30, 2023. The filing primarily consists of a press release detailing these results. While specific financial figures are not detailed within the 8-K document itself, investors are directed to Exhibit 99.1, the press release, for comprehensive details on revenue, earnings, and other key performance indicators. This report serves as notification of the earnings release and includes standard forward-looking statements and risk disclosures common in such filings. Investors should refer to the furnished press release for the actual financial performance and outlook, as the 8-K itself is procedural. The accompanying risk factors highlight potential challenges such as healthcare cost trends, regulatory changes, cyber security threats, and competitive pressures that could impact future results.

Elevance Health, Inc. (ELV) reported strong financial results for the quarter ending June 30, 2023. Total revenues increased by 13.0% year-over-year to $43.7 billion, driven by higher premium revenues in the Health Benefits segment and growth in CarelonRx. Net income saw a robust increase of 13.6% to $1.86 billion, or $7.79 per diluted share, up from $1.63 billion, or $6.73 per diluted share, in the prior year period. This performance was supported by operating gains across all segments, improved investment income, and a decrease in net losses on financial instruments. The company also experienced significant growth in medical membership, particularly in its Medicaid and Medicare Advantage offerings, contributing to the overall positive financial trajectory. Elevance Health continues to execute on its strategic initiatives, including brand portfolio reorganization and acquisitions, positioning itself for continued growth and value creation. The company's balance sheet remains strong, with total assets growing to $109.2 billion from $102.8 billion at the end of the previous year. Key drivers of this asset growth include increases in cash and cash equivalents, fixed maturity securities, and goodwill, reflecting business acquisitions. Liabilities also increased, primarily due to higher long-term debt and medical claims payable. Shareholders' equity strengthened, demonstrating the company's ability to generate and retain earnings. Operating cash flow for the six months ended June 30, 2023, was substantial at $8.4 billion, indicating healthy operational cash generation. Elevance Health also returned capital to shareholders through dividends and share repurchases, underscoring its commitment to shareholder value.

Elevance Health, Inc. (ELV) has reaffirmed its full-year 2023 net income guidance for investors. The company expects net income to be greater than $29.50 per share, which includes approximately $3.20 per share attributable to net unfavorable items. Excluding these specific items, Elevance Health anticipates adjusted net income to exceed $32.70 per share. This guidance remains consistent with the financial outlook provided in the first quarter of 2023 and does not incorporate any additional adjustment items beyond those previously reported. This reaffirmation of guidance suggests management's confidence in the company's ongoing performance and its ability to navigate the current business environment. Investors should note that the guidance is subject to the inherent risks and uncertainties outlined in the company's forward-looking statements, including potential impacts from healthcare cost trends, regulatory changes, and competitive pressures. The company intends to communicate these projections and other forward-looking information during upcoming investor meetings.

Elevance Health, Inc. (ELV) filed an 8-K on May 10, 2023, reporting the results of its Annual Meeting of Shareholders held on May 9, 2023. The key takeaway for investors is the overwhelmingly positive shareholder support for the election of directors and the company's executive compensation practices, as well as the ratification of Ernst & Young LLP as the independent auditor. These outcomes suggest continued confidence in the current leadership and financial oversight of the company. Furthermore, shareholders have indicated a preference for an annual advisory vote on executive compensation. Notably, two shareholder proposals, one concerning the right to call a special meeting and another requesting annual reporting from third parties seeking financial support, did not receive majority approval. This indicates that the current governance structure and reporting practices remain largely intact as determined by the shareholder vote.

Elevance Health, Inc. (ELV) filed an 8-K on April 19, 2023, primarily to furnish a press release detailing its financial results for the first quarter ended March 31, 2023. While the 8-K itself does not contain the specific financial figures, it serves as notification to the market that the company has publicly disclosed its Q1 2023 performance. Investors should refer to the furnished press release (Exhibit 99.1) for detailed operational and financial outcomes, including revenue, earnings, membership, and any updated guidance. This filing also includes standard forward-looking statements, cautioning investors about the inherent risks and uncertainties that could cause actual results to differ from projections. Key risk factors mentioned include healthcare cost trends, enrollment fluctuations, regulatory changes, cyber security threats, and competitive pressures, among others. Investors are encouraged to review these risks alongside the company's financial performance to gain a comprehensive understanding of Elevance Health's current position and future outlook.

Elevance Health, Inc. (ELV) reported strong financial results for the first quarter of 2023, exceeding the previous year's performance. Total operating revenue increased by 10.6% to $41.9 billion, driven by robust membership growth across key segments including Medicaid, Medicare Advantage, and commercial fee-based plans. Net income saw a significant jump of 12.6% to $2.0 billion, translating to a diluted EPS of $8.30, up 13.4% year-over-year. This growth was supported by improved operating gains in its business segments, particularly Health Benefits and CarelonRx, alongside higher net investment income. The company also reported a substantial increase in operating cash flow, nearly tripling to $6.5 billion, bolstered by early premium receipts from CMS and positive working capital movements. Strategically, Elevance Health continues to evolve its brand portfolio and operational structure, with a new segment reporting alignment implemented in Q1 2023. The company also announced two significant M&A activities: the agreement to acquire Blue Cross Blue Shield of Louisiana and the pending sale of its life and disability businesses. These moves underscore Elevance Health's commitment to its long-term strategy of becoming a trusted health partner and expanding its integrated care solutions.

Elevance Health, Inc. (ELV) has filed a Current Report (8-K) on March 22, 2023, primarily to announce its upcoming Investor Conference scheduled for March 23, 2023. During this conference, company officers are expected to reaffirm the previously issued full-year 2023 financial guidance. Additionally, Elevance Health plans to discuss its long-term financial targets extending through 2027. This event presents a key opportunity for investors to gain deeper insights into the company's strategic outlook and financial trajectory. While no new financial results or material changes were disclosed in this specific filing, the reaffirmation of guidance and the discussion of long-term targets signal management's confidence in their current business plans and future performance. Investors should pay close attention to the Investor Conference for more detailed information and any updates that may emerge. The company has also provided a standard forward-looking statement disclaimer, cautioning about the inherent risks and uncertainties in their projections.

Elevance Health, Inc. (ELV) announced a key executive leadership transition in its 8-K filing dated February 22, 2023. Gloria M. McCarthy will be stepping down from her role as Executive Vice President and Chief Administrative Officer, effective April 1, 2023. She will transition to a new position as Special Advisor to the Chief Executive Officer. This change in the Chief Administrative Officer role is the primary focus of this filing. Investors should monitor how this transition impacts operational oversight and administrative functions within the company. While McCarthy's move to a special advisor role suggests a continued, albeit different, involvement, the specific responsibilities and impact on strategic execution will be of interest going forward.

Elevance Health, Inc. (ELV) reported strong performance for the fiscal year ended December 31, 2022, demonstrating resilience and strategic growth. The company experienced a significant increase in total operating revenue, primarily driven by robust membership growth in its Government Business segment, particularly within Medicaid, bolstered by the temporary suspension of eligibility recertifications due to the COVID-19 pandemic. Acquisitions in the Medicaid space also contributed positively to revenue. While net income saw a slight decrease year-over-year, largely due to realized losses on financial instruments and increased amortization, the company maintained a strong operating gain across all segments. Elevance Health continues to focus on its transformation into a lifetime, trusted health partner, expanding its brand portfolio and optimizing its business operations. The company also highlighted its commitment to shareholder returns through share repurchases and dividends, underpinned by solid liquidity and capital resources. Looking ahead, Elevance Health is strategically positioned to benefit from ongoing healthcare trends, including potential growth in the individual exchange market as Medicaid eligibility recertifications resume. The company's diversification across commercial, government, and specialty segments, coupled with its integrated capabilities in pharmacy benefits management (CarelonRx) and health services (Carelon Services), provides a solid foundation for future expansion and profitability. Investors should monitor the company's integration of recent acquisitions and its continued progress in achieving its 'whole health' strategy.

Elevance Health, Inc. (ELV) announced the successful closing of a significant notes offering on February 8, 2023, raising approximately $2.57 billion in net proceeds. This offering comprises three tranches of senior unsecured notes: $500 million of 4.900% Notes due 2026, $1 billion of 4.750% Notes due 2033, and $1.1 billion of 5.125% Notes due 2053. The company intends to use these proceeds for general corporate purposes, including funding potential acquisitions, repaying existing debt, and repurchasing its common stock. This capital raise provides Elevance Health with substantial financial flexibility. Investors should note the diverse maturity dates of the notes, offering a range of durations for fixed-income exposure. The proceeds' intended use suggests strategic initiatives, including potential M&A activity and shareholder return programs, which could be key drivers of future company growth and valuation.